United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly St...
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
clinical improvement by 47%, in predominantly pre-treated patients with pulmonary arterial hypertension ( PAH Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, combining potent receptor affinity with continuous exposure to deliver long-term, durable efficacy and disease-mitigating outcomes United Therapeutics intends to submit a New Drug Application ( NDA ) for ralinepag to the U.S. Food and Drug Administration ( FDA ) by the second half of 2026 United Therapeutics will host a webcast at 8:30 a.m. Eastern Time today to further discuss the study results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 02, 2026 BUSINESS WIRE )--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared with placebo in patien
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (UTHR) had its price target raised by UBS Group AG from $655.00 to $705.00. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation to Present at the Leerink Global Healthcare ConferenceBusiness Wire
- United Therapeutics (UTHR) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- UTHR's page on the SEC website